Leprosy

Clinics in Dermatology

Volumn 25, Issue 2, 2007, Pages 165-172

  Walker, Stephen L ^a   Lockwood, Dina N J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; CLARITHROMYCIN; CLOFAZIMINE; COLCHICINE; CORTICOSTEROID; DAPSONE; MINOCYCLINE; OFLOXACIN; PEFLOXACIN; PENTOXIFYLLINE; PREDNISOLONE; RIFAMPICIN; THALIDOMIDE;

ARTICLE; BLINDNESS; BODY FLUID; CLINICAL FEATURE; CONJUNCTIVA; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; ENTEROPATHY; EPISTAXIS; ERADICATION THERAPY; ERYTHEMA NODOSUM LEPROSUM; HEMOLYSIS; HUMAN; ICHTHYOSIS; LAGOPHTHALMOS; LEPROMATOUS LEPROSY; LEPROSY; MULTIBACILLARY LEPROSY; MYCOBACTERIUM LEPRAE; NEURITIS; NEUROPATHY; NEUROTOXICITY; NOSE DISEASE; NOSE STIFFNESS; PATIENT EDUCATION; PAUCIBACILLARY LEPROSY; PHOCOMELIA; PREGNANCY; PRIORITY JOURNAL; REVERSAL REACTION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN; SKIN DEFECT; SKIN INFLAMMATION; SOCIOECONOMICS; SOCIOTHERAPY; TERATOGENICITY; TESTIS ATROPHY; TUBERCULOID LEPROSY;

CLOFAZIMINE; DAPSONE; HUMANS; LEPROSTATIC AGENTS; LEPROSY, LEPROMATOUS; RIFAMPIN;

EID: 33847655164     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2006.05.012     Document Type: Article

References (41)

1. Lockwood D.N.J. Leprosy. In: Burns D.A., Breathnach S.M., Cox N.H., and Griffiths C.E.M. (Eds). Rook's textbook of dermatology. 7th ed. vol. 2 (2004), Blackwell Publishing, Oxford 29.1-29.21
2. Global leprosy situation, 2005. Wkly Epidemiol Rec 80 34 (2005) 289-295
3. Britton W.J., and Lockwood D.N.J. Leprosy. Lancet 363 (2004) 1209-1219
4. Ridley D.S., and Jopling W.H. Classification of leprosy according to immunity. Int J Lepr 34 (1966) 255-273
5. van Brakel W.H., Nicholls P.G., Das L., et al. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev 76 (2005) 14-34
6. www.who.int/lep/disease/Eliminate_Leprosy_V8.pdf
7. Pfaltzgraff R.E., and Ramu G. Clinical leprosy. In: Hastings R.C. (Ed). Leprosy. 2nd ed. (1994), Churchill Livingstone, Edinburgh 237-290
8. Lockwood D.N.J., and Reid A.J.C. The diagnosis of leprosy is delayed in the United Kingdom. Q J Med 94 (2001) 207-212
9. Brand P.W. Temperature variation and leprosy deformity. Int J Lepr 27 (1959) 1-7
10. Abraham S., Ebenezer G.J., and Jesudasan K. Diffuse alopecia of the scalp in borderline-lepromatous leprosy in an Indian patient. Lepr Rev 68 (1997) 336-340
11. Gummer C.L., Starley J.N., Dawber R.P., and Pearson J.M. The distribution of Mycobacterium leprae in the hair follicle of the eyebrow. Int J Lepr Other Mycobact Dis 51 (1983) 205-210
12. Pakti A.H., and Baran R. Significance of nail changes in leprosy: a clinical review of 357 cases. Semin Dermatol 10 (1991) 77-81
13. Croft R.P., Richardus J.H., Nicholls P.G., and Smith W.C. Nerve function impairment in leprosy: design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Lepr Rev 70 (1999) 140-159
14. Facer P., Mathur R., Pandya S.S., et al. Correlation of quantitative tests of nerve and target organ dysfunction with skin immunohistology in leprosy. Brain 121 (1998) 2239-2247
15. van Brakel W.H., and Khawas I.B. Silent neuropathy in leprosy: an epidemiological description. Lepr Rev 65 (1994) 350-360
16. ffytche T.J. The prevalence of disabling ocular complications of leprosy: a global study. Indian J Lepr 70 (1998) 49-59
17. van Brakel W.H., Khawas I.B., and Lucas S.B. Reactions in leprosy: an epidemiological study of 386 patients in West Nepal. Lepr Rev 65 (1994) 190-203
18. Manandhar R., LeMaster J.W., and Roche P.W. Risk factors for erythema nodosum leprosum. Int J Lepr Other Mycobact Dis 67 (1999) 270-278
19. Sarno E.N., Grau G.E., Vieira L.M., and Nery J.A. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol 84 (1991) 103-108
20. Rijal A., Agrawal S., Agarwalla A., and Lakhey M. Bullous erythema nodosum leprosum: a case report from Nepal. Lepr Rev 75 (2004) 177-180
21. Moschella S.L. Primary diffuse lepromatous leprosy with erythema necrotisans (Lucio phenomenon). Arch Dermatol 97 (1968) 593-594
22. Sehgal V. Contemplative immune mechanism of Lucio phenomenon and its global status. J Dermatol 14 (1987) 580-585
23. Lockwood D.N.J., and Sinha H.H. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis 67 (1999) 6-12
24. Ustianowski A.P., Lawn S.D., and Lockwood D.N.J. Interactions between HIV infection and leprosy: a paradox. Lancet Infect Dis 6 (2006) 350-360
25. Faye O., N'Diaye H.A., Keita S., et al. High prevalence of non-leprotic hypochromic patches among children in a rural area of Mali, West Africa. Lepr Rev 76 (2005) 144-146
26. Naik R.P., Srinivas C.R., and Rao R.V. Thickening of peripheral nerves in neurofibromatosis. Indian J Lepr 57 (1985) 876-878
27. World Health Organisation. Chemotherapy of leprosy for control programmes. Tech Rep Ser (1982), WHO, Geneva 675
28. Lockwood D.N.J., and Kumar B. Treatment of leprosy. BMJ 328 (2004) 1447-1448
29. www.clinicalevidence.com
30. Jopling W.H. Complications of treatment with clofazimine (Lamprene: B663). Lepr Rev 47 (1976) 1-3
31. Atkinson Jr. A.J., Sheagren J.N., Barba Rubio J., and Knight V. Evaluation of B.663 in human leprosy. Int J Lepr Other Mycobact Dis 35 (1967) 119-127
32. Degowin R.L., Eppes R.B., Powell R.D., and Carson P.E. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull World Health Organ 35 (1966) 165-179
33. Tomecki K.J., Catalano C.J., Cross H., and Newcombe L. An intensive self care training programme reduces admissions for the treatment of plantar ulcers. Lepr Rev 72 (2001) 276-284
34. Simons J.J., and Morales A. Minocycline and generalized cutaneous pigmentation. J Am Acad Dermatol 33 (1980) 244-247
35. Croft R.P., Nicholls P.G., Steyerberg E.W., et al. A clinical prediction rule for nerve function impairment in leprosy patients-revisited after 5 years of follow-up. Lepr Rev 74 (2003) 35-41
36. van Brakel W.H., and Khawas I.B. Nerve function impairment in leprosy: a clinical and epidemiological study-Part 2 Results of steroid treatment. Lepr Rev 67 (1996) 104-118
37. Smith W.C., Anderson A.M., Withington S.G., et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ 328 (2004) 1459
38. WHO Expert Committee on Leprosy-Fifth Report. Tech Rep Ser (1977), World Health Organisation, Geneva 607
39. Moreira A.L., Kaplan G., Villahermosa L.G., et al. Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Int J Lepr Other Mycobact Dis 66 (1998) 61-65
40. Cross H., and Newcombe L. An intensive self care training programme reduces admissions for the treatment of plantar ulcers. Lepr Rev 72 3 (2001) 276-284
41. Nicholls P.G. Guidelines for social and economic rehabilitation. Lepr Rev 71 (2000) 422-465